Home › Compare › ATXMF vs ABBV
ATXMF yields 71428.57% · ABBV yields 3.06%● Live data
📍 ATXMF pulled ahead of the other in Year 1
Combined, ATXMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ATXMF + ABBV for your $10,000?
Advantex Marketing International Inc. operates as an aggregator of independent merchants in Canada. The company operates through Merchant Cash Advance, Program, and Aeroplan Program segments. It also provides merchant cash advance (MCA) and loyalty marketing services to its community of merchants. The MCA meets working capital needs of merchants; and loyalty marketing provides merchants an economic way to market their establishments through its re-seller relationship with Aeroplan loyalty program. In addition, the company provides the Aeroplan program that allows members to earn aeroplan points on purchases at merchants. Further, the company's merchant partners operate in various business segments, including restaurants; independent inns, resorts, and selected hotels; spas; retailers of men's and ladies fashion, footwear, and accessories; florists and garden centers; health and beauty centers; gift stores; and home décor. Advantex Marketing International Inc. was incorporated in 1994 and is headquartered in Toronto, Canada.
Full ATXMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.